Moody Aldrich Partners LLC Lowers Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Moody Aldrich Partners LLC reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 10.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 96,737 shares of the biopharmaceutical company's stock after selling 10,878 shares during the period. Halozyme Therapeutics makes up about 1.3% of Moody Aldrich Partners LLC's holdings, making the stock its 19th largest holding. Moody Aldrich Partners LLC owned about 0.08% of Halozyme Therapeutics worth $6,173,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Park Place Capital Corp raised its stake in shares of Halozyme Therapeutics by 20.1% in the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after acquiring an additional 182 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 197 shares in the last quarter. Bessemer Group Inc. raised its stake in shares of Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 207 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Halozyme Therapeutics by 12.5% in the first quarter. Parallel Advisors LLC now owns 1,875 shares of the biopharmaceutical company's stock valued at $120,000 after acquiring an additional 208 shares in the last quarter. Finally, Baird Financial Group Inc. raised its stake in shares of Halozyme Therapeutics by 2.0% in the fourth quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company's stock valued at $532,000 after acquiring an additional 221 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $0.21 during mid-day trading on Friday, hitting $54.05. 868,065 shares of the stock were exchanged, compared to its average volume of 1,752,173. The stock's fifty day simple moving average is $55.49 and its two-hundred day simple moving average is $56.57. The stock has a market capitalization of $6.66 billion, a price-to-earnings ratio of 14.38, a P/E/G ratio of 0.36 and a beta of 1.15. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $70.51. The company has a debt-to-equity ratio of 3.13, a quick ratio of 7.30 and a current ratio of 8.39.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.13. The company had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The business's quarterly revenue was up 35.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.79 earnings per share. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $53.73, for a total transaction of $1,074,600.00. Following the transaction, the chief executive officer owned 733,719 shares of the company's stock, valued at $39,422,721.87. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Jeffrey William Henderson sold 4,497 shares of the firm's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $60.37, for a total value of $271,483.89. Following the transaction, the director directly owned 28,611 shares in the company, valued at approximately $1,727,246.07. This represents a 13.58% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,497 shares of company stock worth $2,405,284. Corporate insiders own 2.40% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on HALO shares. JPMorgan Chase & Co. increased their price objective on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Leerink Partnrs cut Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. HC Wainwright restated a "buy" rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, May 29th. Leerink Partners cut Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target on the stock. in a research note on Tuesday, May 13th. Finally, Benchmark cut Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics has an average rating of "Hold" and a consensus target price of $61.90.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.